Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19
August 19, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis. and MORGAN HILL, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit,...
Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology
August 12, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced its plan to develop a test to potentially triage COVID-19 patients into those likely versus...
Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19
August 10, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI),...
Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates
August 06, 2020 16:05 ET
|
Monopar Therapeutics Inc.
CHICAGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary...
Monopar Therapeutics Reports First Quarter 2020 Financial Results and Business Updates
May 07, 2020 09:00 ET
|
Monopar Therapeutics Inc.
CHICAGO, May 07, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics...
Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma
February 18, 2020 09:00 ET
|
Monopar Therapeutics Inc.
CHICAGO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ: MNPR) today announced it has been granted Orphan Drug Designation from the European Commission for its drug candidate...
Monopar Therapeutics Inc. Announces Closing of Initial Public Offering of Common Stock
December 23, 2019 12:30 ET
|
Monopar Therapeutics Inc.
CHICAGO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced the closing of its initial public offering of 1,277,778 shares of common stock, including the underwriters’...
Monopar Therapeutics Inc. Announces Full Exercise of Over-Allotment by Underwriters
December 20, 2019 16:46 ET
|
Monopar Therapeutics Inc.
CHICAGO, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced that the underwriters of its previously announced initial public offering of common stock have exercised in full...
Monopar Therapeutics Inc. Announces Pricing of Initial Public Offering
December 18, 2019 19:52 ET
|
Monopar Therapeutics Inc.
CHICAGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced that it has priced an initial public offering of 1,111,112 shares of its common stock at $8.00 per share. The...